Search results
-
PharmEco to Launch Oncology Drug Production with ₽9.1 Billion Investment
The PharmEco Group of Companies will build a pharmaceutical manufacturing facility for oncology treatments in Chernogolovka, Moscow Region, by 2030. The total investment in the project is estimated at 9.1 billion rubles. A trilateral agreement was signed during the St. Petersburg International Economic Forum (SPIEF 2025) between the Ministry of Investment, Industry and Science of…
-
Russian Government Introduces New Procedure for Releasing Medicines into Civil Circulation
The Russian government has approved updated regulations governing the release of medicines into civil circulation. The new rules cover: Various versions of the draft regulation were published by the Ministry of Health in January and February 2025. The newly adopted procedure replaces the 2019 regulation, which was originally set to expire in September 2025. The…
-
National Preference Benefits Will Now Apply to All Russian-Made Medicines, Not Just Those on the Vital Drugs List
The Russian government has amended its decree on measures for granting national treatment in the procurement of goods, works, and services for state and municipal needs. The original document, adopted in late December 2024, extended the “third-party exclusion” mechanism (“the second extra one”) to the purchase of medicines from the list of vital and essential…
-
Medicine Sales in Russia Surpass 1 Trillion Rubles Since Beginning of the Year
From January to April 2025, medicine sales in Russia reached 1.03 trillion rubles. Compared to the same period in 2024, this represents a 17% increase. In physical volume, however, the market grew by only 2%, with 1.92 billion packages sold. According to a report by the analytics company AlphaRM, the pharmaceutical market exceeded 1 trillion…
-
Pfizer CEO Proposes a “Pharmaceutical NATO” with Fixed Spending on Medicines
Pfizer CEO Albert Bourla has called on European countries to increase their spending on medicines. He proposed setting a fixed percentage of GDP per capita for such expenditures, similar to NATO’s defense spending commitments. Speaking at the annual Goldman Sachs healthcare conference, Bourla urged developed countries to boost funding for innovative drugs. The text of…
-
“Geropharm” receives another compulsory license for semaglutide
The Russian government has granted Geropharm permission to use, without the patent holder’s consent, a portfolio of patents protecting Novo Nordisk’s exclusive rights to semaglutide until the end of 2025. Similar decisions had previously been made for two other Russian companies — PSK Pharma and Promomed — in late 2024. Geropharm had already been covered…
-
Bill on penalties for “medication intoxication” while driving passes first reading
On Tuesday, the State Duma passed in the first reading a government-sponsored bill introducing administrative liability for drivers who operate vehicles under the influence of certain medications. Bill No. 379447-8 proposes amendments to Articles 12.8 and 12.27 (Part 3) of the Russian Code of Administrative Offenses (KoAP), expanding the scope of punishable intoxication. Under the…
-
FAS to investigate Russian pharmaceutical market over rising drug prices
The Federal Antimonopoly Service (FAS) of Russia plans to investigate several domestic pharmaceutical companies due to signs of unjustified price increases for drugs not included in the list of vital and essential medicines (VED). This was announced by Timofey Nizhegorodtsev, Deputy Head of the FAS, during the Semashko Russian Pharmaceutical Forum. “Many companies may soon…
-
Russia develops compounds capable of significantly suppressing tumor cell growth
The discovery could greatly reduce chemotherapy toxicity and change future approaches to cancer treatment. Scientists at Ural Federal University (UrFU) have created carbene-based platinum complexes that suppress tumor cell growth ten times more effectively than cisplatin — one of the most widely used chemotherapy drugs. The discovery could help fight tumors that have developed resistance…
-
“Genealogical Extract”: Pharmaceutical Industry Discusses Mechanisms for Defining Manufacturing Nationality
At the Semashko Russian Pharmaceutical Forum, domestic and international pharmaceutical companies gathered to discuss fair mechanisms for determining the level of localization in drug manufacturing and what support measures could help the industry invest more in development. Russia’s Ministry of Industry and Trade (Minpromtorg), the sector’s key regulator, reminded participants that it is currently working…